SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Strategy, Inc. engages in the provision of enterprise analytics and mobility software. The firm designs, develops, markets, and sells software platforms through licensing arrangements and cloud-based subscriptions and related services. Its product packages include Hyper. The company was founded by Michael J. Saylor and Sanjeev K. Bansal on November 17, 1989, and is headquartered in Vienna, VA.

Strategy Inc. - Ordinary Shares - Class A

Strategy

Strategy is trending as Bitcoin's pullback impacts the stock, leading to community discussions about its correlation with BTC and sustainability. Concerns are emerging regarding Strategy's debt and ability to cover dividend payments, with some speculating about potential liquidation risks. Despite negativity, some investors view the dip as a buying opportunity, citing the company's substantial Bitcoin holdings and potential for a rebound.

Warner Bros. Discovery, Inc. is a premier global media and entertainment company, which engages in the provision of a differentiated portfolio of content, brands, and franchises across television, film, streaming, and gaming. It operates through the following segments: Studios, Networks, Direct-to-Consumer (DTC), and Corporate. The Studios segment includes producing and releasing feature films for initial exhibition in theaters, producing and initial licensing television programs to networks services as well as third parties, distributing films and television programs to various third party, internal television, and streaming services, distribution through the home entertainment market related consumer products, and themed experience licensing and interactive gaming. The Networks segment focuses on domestic and international television networks. The DTC segment is involved in premium pay-television and streaming services. The company was founded on June 17, 1985 and is headquartered in New York, NY.

Warner Bros. Discovery Inc - Ordinary Shares - Class A

Warner Bros Discovery Inc

WBD is trending amid speculation of a potential bidding war, with reports suggesting Paramount, Comcast, and Netflix are preparing offers. Community discussions revolve around potential buyout prices and the strategic value of WBD's assets, including HBO and Warner Bros. studios. The stock's movement reflects both optimism for a high-value deal and concerns about the company's debt.

StarkNet is a permissionless decentralized Layer 2 (L2) validity rollup, built to allow Ethereum to scale via cryptographic protocols called STARKs, without compromising Ethereum’s core principles of decentralization, transparency, inclusivity and security. The StarkNet Token is needed to operate the ecosystem, maintain and secure it, decide on its values and strategic goals, and direct its evolution. This token will be required for (i) governance, (ii) payment of transaction fees on StarkNet, and (iii) participation in StarkNet’s consensus mechanism.

Strike Coin

Starknet ($STRK) is trending due to increased staking, incentives for BTCFi, and the potential for scaling privacy solutions. Community members are discussing its relationship to ZCash ($ZEC) and the possibility of a "Ztarknet", which would integrate privacy and scalability. The recent surge in staking and new developments in BTCFi are driving renewed interest in the token.

Sigma Lithium Corp. engages in the producing of a lithium property. It focuses its project in Minas Gerais. The firm also plans to build a world-class commercial-scale lithium concentration plant. The company was founded on June 8, 2011 and is headquartered in Sao Paulo, Brazil.

Sigma Lithium Corporation

Sigma Lithium ($SGML) is trending as investors digest recent Q3 earnings reports and insider buying activity, while lithium prices show signs of recovery. The community is weighing the company's financial health, production capacity, and potential for a price surge amidst broader discussions about the lithium market's future and potential takeover scenarios. Bullish sentiment is building, driven by rising lithium prices and the anticipation of future earnings reports.

Bitcoin is the world's first decentralized cryptocurrency, created in 2009 by the pseudonymous Satoshi Nakamoto. It enables peer-to-peer electronic cash transactions without intermediaries like banks or governments, operating on a blockchain secured by Proof of Work mining and the SHA-256 cryptographic algorithm.   With a fixed supply cap of 21 million coins and programmatic halvings every four years that reduce miner rewards, Bitcoin is designed as a deflationary digital asset often called "digital gold." Its value stems from solving the double-spending problem without trusted intermediaries, creating the first truly scarce digital asset with censorship resistance and permissionless access that no government, corporation, or individual can control.  Bitcoin operates as a decentralized peer-to-peer network where transactions are recorded on a public ledger called the blockchain, distributed across thousands of computers globally. Transactions are grouped into blocks added approximately every 10 minutes through mining, where specialized computers compete to solve complex mathematical puzzles.   Bitcoin has achieved mainstream adoption through multiple vectors. The January 2024 SEC approval of 11 spot Bitcoin ETFs opened Bitcoin investment to traditional finance participants, and corporations like Strategy (formerly MicroStrategy) are using Bitcoin as a treasury reserve asset to protect against currency debasement, offering MSTR holders amplified exposure to Bitcoin.   The Bitcoin ecosystem continues to evolve with innovations like Ordinals, which emerged in January 2023 to enable NFT-like functionality directly on Bitcoin, and BRC-20 tokens, an experimental standard for creating fungible tokens using Ordinal inscriptions. BTCFi (Bitcoin Finance) represents emerging financial applications extending beyond Bitcoin's traditional role, with protocols like Babylon allowing Bitcoin holders to stake BTC to secure Proof of Stake chains.

Bitcoin

Bitcoin is trending as it tests key support levels, sparking debate about a potential rebound or further decline. Community discussions revolve around Michael Saylor's continued accumulation and the influence of broader market factors like potential Fed rate cuts and macroeconomic data. Some traders are pointing to technical indicators suggesting oversold conditions and a possible relief rally, while others remain bearish, citing historical patterns and potential risks.

WeShop Holdings Ltd. engages in providing a shoppable social network. It offers shopping in fashion and accessories, health and beauty, home and DIY, food and drink, travel and holidays, tech and electronics, and other popular categories. It includes a library of shoppable product reviews from a digital online shopping mall on mobile devices. The company was founded by John Garner on September 21, 2012 and is headquartered in Jersey, the United Kingdom.

WeShop Holdings Ltd - Ordinary Shares - Class A

Wasatch Pharmaceutical Inc

Wasatch Pharmaceutical (WSHP) is trending due to its recent direct listing, with the community actively discussing its volatile price action and potential trading opportunities. Some traders are taking profits after an initial surge, while others are closely monitoring the chart for entry points. The direct listing itself is driving significant interest in the stock.

iShares Bitcoin Trust ETF - iShares Bitcoin Trust Beneficial Interest

iShares Bitcoin ETF

IBIT is trending as the community discusses Bitcoin's price action and potential correlation with traditional markets. Community members are debating whether recent dips present buying opportunities or signal further correction, and the ETF's performance relative to Bitcoin itself is also being analyzed. Discussions also include potential impacts from macroeconomic factors and large institutional players.

Sociedad Quimica y Minera de Chile SA engages in the production and distribution of fertilizers, potassium nitrate, iodine, and lithium chemicals. It operates through the following segments: Specialty Plant Nutrients, Iodine and Derivatives, Lithium and Derivatives, Industrial Chemicals, Potassium, and Other Products and Services. The Specialty Plant Nutrients segment produces potassium nitrate, sodium nitrate, sodium potassium nitrate, and specialty blends. The Iodine and Derivatives segment manufactures iodine and iodine derivatives, which are used in a wide range of medical, pharmaceutical, agricultural, and industrial applications. The Lithium and Derivatives segment covers lithium carbonate for electrochemical materials for batteries, frits for the ceramic and enamel industries, heat-resistant glass, air conditioning chemicals, continuous casting powder for steel extrusion, primary aluminum smelting process, pharmaceuticals, and lithium derivatives. The Industrial Chemicals segment comprises industrial chemicals including sodium nitrate, potassium nitrate, and boric acid. The Potassium segment produces potassium chloride and potassium sulfate. The Other Products and Services segment deals with other fertilizers and blends. The company was founded on June 17, 1968 and is headquartered in Santiago, Chile.

Sociedad Quimica Y Minera de Chile S.A. - ADR

Chemical & Mining Co. of Chile Inc.

SQM is trending as investors digest news of a potential agreement with Codelco regarding lithium operations, sparking debate about the long-term benefits. Community discussions center on the impact of lithium prices and production strategies on the stock's outlook, with some analysts adjusting price targets. The stock's dividend yield and exposure to the EV battery market are also key talking points.

zkSync

ZK is trending as community members discuss its potential for scaling Ethereum and recent price movements, with some highlighting upcoming token unlocks.  Bullish sentiment seems to be building around the ZK technology and integrations with major players, sparking conversations about future price targets. The community is also closely watching for potential pullbacks and market dips.

Grindr, Inc. engages in the operation of a social media network application for the gay, bi, trans, queer, and other members of the LGBTQ+ community. The company was founded in 2009 and is headquartered in West Hollywood, CA.

Grindr Inc - Ordinary Shares - Class A

Grindr Inc

Grindr is trending amid buyout speculation, with community members discussing the potential deal's impact and likelihood after recent insider selling and strong earnings. Some investors believe the stock is undervalued, pointing to analyst price targets and potential deal bumps, while others are wary, citing insider activity and deal uncertainty. Discussions also cover the company's financial performance and unique market position.

statis crypto Watchlist

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Avantax Advisory Services Inc. Buys 34,861 Shares of Merck & Co., Inc. $MRK

Avantax Advisory Services Inc. lifted its stake in shares of Merck & Co., Inc. (NYSE:MRK - Free Report) by 15.2% during the second quarter, according to its most recent filing with the Securities and...

<ul class="summary-bullets"><li>Merck’s all-cash agreement grants it access to Cidara’s lead flu-prevention antibody, CD388, which has received FDA Breakthrough Therapy designation and is currently in late-stage studies enrolling more than 6,000 participants.</li><li>Major brokerages moved to neutral stances following the announcement.</li><li>Retail traders reacted on Stocktwits, with many celebrating long-held gains.</li></ul><p>Cidara Therapeutics, up more than 700% this year, more than doubled on Friday after Merck unveiled a $9.2 billion all-cash takeover, only for major Wall Street firms to turn neutral on the biotech following the deal’s announcement.</p><p>The deal values Cidara at $221.50 per share, representing a roughly 109% premium to Thursday’s close, and is expected to close in the first quarter of 2026, subject to customary conditions.</p><h2 class="st-heading-2"><strong>Analysts Cut Ratings After Deal Announcement</strong></h2><p>Despite the stock surge, major brokerages shifted to neutral stances across the board. Morgan Stanley downgraded Cidara to ‘Equal Weight’, JPMorgan moved to ‘Neutral’, RBC Capital to ‘Sector Perform’, and Needham shifted to ‘Hold’. H.C. Wainwright also stepped back to ‘Neutral’.&nbsp;</p><h2 class="st-heading-2"><strong>Merck’s Strategic Push Ahead Of Keytruda Patent Expiry</strong></h2><p>Merck said&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/merck-to-buy-cidara-in-9.2-billion-dollar-deal/cLPQJxLRE44">the takeover</a> strengthens its respiratory pipeline ahead of the anticipated 2028 patent loss for Keytruda, its top-selling cancer therapy that generated more than $25 billion last year. The move follows Merck’s $10 billion acquisition of Verona Pharma in July, part of a series of large deals aimed at building future revenue streams.</p><p>Cidara brings Merck its lead candidate, CD388, a long-acting antibody designed to prevent influenza infection in high-risk individuals. The U.S. Food and Drug Administration has granted CD388 Breakthrough Therapy designation, potentially speeding its review. The program is currently in late-stage studies across high-risk populations, including immunosuppressed patients who cannot receive seasonal flu vaccines and adults aged 65 and older. More than 6,000 participants are expected to be enrolled globally by the end of the month.</p><h2 class="st-heading-2"><strong>Competitive Bidding And Rising Value</strong></h2><p>Discussions&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/cidara-therapeutics-stock-soars-42-after-hours-on-merck-buyout-buzz/cLPfvfZREEh">reportedly</a> extended late into Thursday as Merck faced competition from another pharmaceutical group before its winning bid was selected. The high demand reflects growing interest in long-acting influenza prevention technologies, particularly for vulnerable populations.</p><p><a href="https://stocktwits.com/symbol/CDTX">Cidara</a> has been among the sector’s strongest performers in recent months. Its shares have been fueled by robust clinical data, speculation about a potential auction, and rising interest in CD388’s commercial prospects. The frenzy comes amid a broader wave of pharmaceutical dealmaking, including Pfizer’s recent win over Novo Nordisk in the race for obesity-drug developer Metsera in a deal worth up to $10 billion.</p><h2 class="st-heading-2"><strong>Stocktwits Users Celebrate Big Payday</strong></h2><p>On Stocktwits, retail sentiment was ‘extremely bullish’ for Cidara and ‘bullish’ for Merck, with both seeing elevated message activity ranging from ‘extremely high’ to ‘high’.</p><p>Some users said they had waited a long time for this outcome and thanked the Cidara team as they exited their positions, while others congratulated holders, noting that the deal delivered major gains for many investors.</p><p><stembedurl>https://stocktwits.com/Tauro83/message/636302166</stembedurl></p><p><stembedurl>https://stocktwits.com/Kabita84/message/636294520</stembedurl></p><p><a href="https://stocktwits.com/symbol/MRK">Merck’s stock</a> has declined 4% so far in 2025.</p><p><i>For updates and corrections, email newsroom[at]stocktwits[dot]com.</i></p>

In this photo illustration, the Cidara Therapeutics logo is seen displayed on a smartphone screen. (Photo Illustration by Thomas Fuller/SOPA Images/LightRocket via Getty Images)

Cidara Therapeutics Stock Rockets Over 700% This Year — Then Wall Street Turns Neutral On Merck Takeover 

Merck’s all-cash agreement grants it access to Cidara’s lead flu-prevention antibody, CD388, which has received FDA Breakthrough Therapy designation and is currently in late-stage studies enrolling more than 6,000 participants.

Equity

Cidara Therapeutics Investor Alert By The Former Attorney General Of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Cidara Therapeutics, Inc. - CDTX

Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (KSF) are investigating the proposed sale of Cidara Therapeutics, Inc. (NasdaqCM: CDTX) to...

Westpac Banking Corp Acquires 3,253 Shares of Merck & Co., Inc. $MRK

Westpac Banking Corp lifted its holdings in Merck & Co., Inc. (NYSE:MRK - Free Report) by 2.8% in the 2nd quarter, according to its most recent Form 13F filing with the Securities and Exchange...

Thoroughbred Financial Services LLC Has $1.31 Million Holdings in Merck & Co., Inc. $MRK

Thoroughbred Financial Services LLC lessened its position in shares of Merck & Co., Inc. (NYSE:MRK - Free Report) by 38.7% in the second quarter, according to its most recent disclosure with the...

WealthShield Partners LLC Lowers Stake in Merck & Co., Inc. $MRK

WealthShield Partners LLC lessened its holdings in Merck & Co., Inc. (NYSE:MRK - Free Report) by 87.8% in the 2nd quarter, according to the company in its most recent 13F filing with the Securities...

Merck & Co., Inc. $MRK Shares Bought by Generali Investments Management Co LLC

Generali Investments Management Co LLC grew its holdings in Merck & Co., Inc. (NYSE:MRK - Free Report) by 30.5% during the 2nd quarter, according to its most recent Form 13F filing with the...

Persistent Asset Partners Ltd Makes New $368,000 Investment in Merck & Co., Inc. $MRK

Persistent Asset Partners Ltd bought a new position in Merck & Co., Inc. (NYSE:MRK - Free Report) in the 2nd quarter, according to its most recent filing with the SEC. The institutional investor...

Thomas Story & Son LLC Takes Position in Merck & Co., Inc. $MRK

Thomas Story & Son LLC purchased a new position in shares of Merck & Co., Inc. (NYSE:MRK - Free Report) during the second quarter, according to its most recent Form 13F filing with the Securities and...

Rockefeller Capital Management L.P. Buys 35,011 Shares of Merck & Co., Inc. $MRK

Rockefeller Capital Management L.P. lifted its stake in shares of Merck & Co., Inc. (NYSE:MRK - Free Report) by 2.9% during the 2nd quarter, according to its most recent disclosure with the...

Merck & Co., Inc. is a health care company, which engages in the provision of health solutions through its prescription medicines, vaccines, biologic therapies, animal health, and consumer care products. It operates through the following segments: Pharmaceutical, Animal Health, and Other. The Pharmaceutical segment includes human health pharmaceutical and vaccine products. The Animal Health segment discovers, develops, manufactures, and markets animal health products, such as pharmaceutical and vaccine products, for the prevention, treatment and control of disease in livestock, and companion animal species. The Other segment consists of sales for the non-reportable segments of healthcare services. The company was founded in 1891 and is headquartered in Rahway, NJ.

Merck & Co Inc

Will NVIDIA ($NVDA) beat quarterly earnings? 
 
*Powered by Polymarket

Stocktwits

) beat quarterly earnings? 
 
*Powered by Polymarket

MRK
Merck & Co Inc

Feed

News

Sentiment

Earnings

Fundamentals

Info

Poll

Latest MRK News

MRKMerck & Co Inc